The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial

Interleukin-18 Promoter Gene Polymorphisms are not Associated with Myocardial Infarction in Type 2 Diabetes in SloveniaType 2 diabetes is a major risk factor for myocardial infarction (MI) and chronic inflammation may play a central role in both diseases. Interleukin (IL)-18 is a potent proinflammatory cytokine, which is considered important in acute coronary syndromes and type 2 diabetes. We investigated the association of the -137 (G>C), polymorphism (rs187238) and the -607 (C<A) polymorphism (rs1946518) of the IL-18 gene promoter region in 495 Caucasians with type 2 diabetes, of whom 169 had MI and 326 subjects had no clinically evident coronary artery disease (controls). We also investigated the impact of these polymorphisms on the serum IL-18 level in subsets of both groups and in a normal group. Genotype distributions of the polymorphisms showed no significant difference between cases and controls. However, IL-18 serum levels were significantly lower in diabetics with the137 CC genotype than in those with other genotypes (241.5 ± 132.7 ng/Lvs.340.2 ± 167.4 ng/L; p <0.05). High sensitivity C-reactive protein and IL-18 serum levels were higher in diabetics in the MI group than in the control group. We conclude that these IL-18 promoter gene polymorphisms are not risk factors for MI in Caucasians with type 2 diabetes.

Download Full-text

Intensive Integrated Therapy of Type 2 Diabetes: Implications for Long-Term Prognosis

Diabetes ◽

10.2337/diabetes.53.suppl_3.s39 ◽

2004 ◽

Vol 53 (Supplement 3) ◽

pp. S39-S47 ◽

Cited By ~ 66

Author(s):

P. Gaede ◽

O. Pedersen

Keyword(s):

Type 2 Diabetes ◽

Integrated Therapy ◽

Long Term Prognosis

Download Full-text

The impact of hidradenitis suppurativa on general health is higher than that of hypertension, congestive heart failure, type 2 diabetes, myocardial infarction and depression

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.16290 ◽

2020 ◽

Vol 34 (8) ◽

Cited By ~ 2

Author(s):

F. Sampogna ◽

L. Fania ◽

C. Mazzanti ◽

S. Pallotta ◽

A. Panebianco ◽

...

Keyword(s):

Myocardial Infarction ◽

Heart Failure ◽

Type 2 Diabetes ◽

Congestive Heart Failure ◽

General Health ◽

Hidradenitis Suppurativa ◽

Failure Type ◽

The Impact

Download Full-text

Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using 18F-FDG PET/MRI

BMJ Open Diabetes Research & Care ◽

10.1136/bmjdrc-2019-001135 ◽

2020 ◽

Vol 8 (1) ◽

pp. e001135 ◽

Cited By ~ 1

Author(s):

Sazan Rasul ◽

Barbara Katharina Geist ◽

Helmut Brath ◽

Pascal Baltzer ◽

Lalith Kumar Shiyam Sundar ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Renal Function ◽

Fdg Pet ◽

Renal Tubules ◽

Initiation Of Therapy ◽

The Impact

IntroductionInhibitors of sodium-glucose linked transporter-2 (SGLT2i) are enhancing glucose excretion in the proximal renal tubules, and thus are increasingly used to lower blood glucose levels in patients with type 2 diabetes mellitus (T2DM). The glucose analog 2-deoxy-2-(18F) fluoro-D-glucose (FDG) can be used to quantify renal function in vivo, and due to an affinity for SGLT2 could also provide information about SGLT2 transporter function. Our objectives in this study were, therefore, to assess the impact of SGLT2i on renal function parameters in patients with T2DM and identify predictive parameters of long-term response to SGLT2i using dynamic FDG positron emission tomography (PET)/MRI.MethodsPET FDG renal function measures such as mean transit time (MTT) and general renal performance (GRP) together with glomerular filtration rate (GFR) were determined in 20 patients with T2DM before (T2DMbaseline) and 2 weeks after initiation of therapy with SGLT2i (T2DMSGLT2i). Additionally, dynamic FDG PET data of 24 healthy subjects were used as controls.ResultsMTT in T2DMbaseline was significantly higher than in healthy controls (5.7 min vs 4.3 min, p=0.012) and significantly decreased to 4.4 min in T2DMSGLT2i (p=0.004). GRP of T2DMSGLT2i was higher than of T2DMbaseline (5.2 vs 4.7, p=0.02) and higher but not significantly than of healthy individuals (5.2 vs 5.1, p=0.34). Expectedly, GFR of healthy participants was significantly higher than of T2DMbaseline and T2DMSGLT2i (122 vs 92 and 86 mL/min/1.73 m², respectively; p<0.001). The higher the GRP value in kidneys of T2DMSGLT2i, the lower was the glycated hemoglobin level 3 months after therapy initiation.ConclusionMTT and GRP values of patients with T2DM shifted significantly toward values of healthy control 2 weeks after therapy with SGLT2i begins. GRP in T2DMSGLT2i was associated with better long-term glycemic response 3 months after initiation of therapy.Trial registration numberNCT03557138.

Download Full-text

Faculty Opinions recommendation of The impact of hidradenitis suppurativa on general health is higher than that of hypertension, congestive heart failure, type 2 diabetes, myocardial infarction and depression.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738399238.793577123 ◽

2020 ◽

Author(s):

Iltefat Hamzavi

Keyword(s):

Myocardial Infarction ◽

Heart Failure ◽

Type 2 Diabetes ◽

Congestive Heart Failure ◽

General Health ◽

Hidradenitis Suppurativa ◽

Failure Type ◽

The Impact

Download Full-text

MYOCARDIAL INFARCTION AND CHRONIC KIDNEY DISEASE: WHAT TO EXPECT?! (review article)

Vestnik ◽

10.53065/kaznmu.2021.63.65.012 ◽

2021 ◽

pp. 73-77

Author(s):

М.А. Нуржанова ◽

А.Е. Темурова ◽

Ж.М. Жанкетаева ◽

Ж.Ш. Бабак ◽

Ш.М. Отеева ◽

...

Keyword(s):

Myocardial Infarction ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Myocardial Revascularization ◽

Review Article ◽

Long Term Prognosis ◽

The Impact ◽

Complications And Mortality ◽

Clinical Problems

Данная обзорная статья посвящена проблеме коморбидных пациентов, а именно для случаев сниженной скорости клубочковой фильтрации (СКФ) и атеросклероза коронарных артерии. Эта проблема является одним из важных моментов в кардиологии и нефрологии, так как Хроническая болезнь почек (ХБП) осложняет Инфаркт миокарда (ИМ) и в целом течения Ишемической болезни сердца (ИБС). В этой работе мы обсуждаем уникальные проблемы ведения этих пациентов, осложнения и смертность на госпитальном этапе, влияние ХБП на долгосрочный прогноз после ИМ, лечение которых проводится с помощью консервативной терапии и реваскуляризации миокарда, с целью призыва на профилактические меры и дальнейших разработок, и выделения доступных методов лечения, сокращения осложнений и госпитализаций, и других клинических проблем. This review article is devoted to the problem of comorbid patients, namely for cases of decreased glomerular filtration rate (GFR) and coronary atherosclerosis. This problem is one of the important points in cardiology and nephrology, since Chronic Kidney Disease (CKD) complicates myocardial infarction (MI) and, in general, the course of coronary heart disease (IHD). In this paper, we discuss the unique problems of managing these patients, complications and mortality at the hospital stage, the impact of CKD on the long-term prognosis after MI, which are treated with conservative therapy and myocardial revascularization. With the aim of calling for preventive measures and further developments, and highlighting available treatment methods, reduction of complications and hospitalizations; and other clinical problems.

Download Full-text

Basal insulin therapy in patients with type 2 diabetes mellitus: aspects of early initiation, advantages, constraints, and prospects

Problems of Endocrinology ◽

10.14341/probl201157353-59 ◽

2011 ◽

Vol 57 (3) ◽

pp. 53-59

Author(s):

O K Vikulova

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Insulin Therapy ◽

Intensive Therapy ◽

Cardiovascular Complications ◽

Optimal Regime ◽

Long Term Prognosis

Intensive control of glycemia starting from the onset of type 2 diabetes mellitus (DM2) is of primary importance for the long-term prognosis of the disease and the reduction of risk of cardiovascular complications. The strategy of early intensive therapy of DM2 thus far remains a matter of fierce dispute among diabetologists. The problem of choice of an optimal regime for the start of insulin therapy does not have an unambiguous solution either. Hypoglycemia is the main factor that traditionally hampers wide application of insulin therapy in patients with type 2 diabetes mellitus. The choice in favour of basal therapy with insulin analogs has the advantage of reaching the target parameters of carbohydrate metabolism at a significantly lower risk of hypoglycemia compared with other strategies of insulin therapy.

Download Full-text